Selank nasal drops, TP-7
Evidence Grade C — Moderate human evidence. 68 published studies, 15 human. 2 registered clinical trials.
Selank is a synthetic peptide developed in Russia, derived from a fragment of an immune system protein (tuftsin). It is used clinically in Russia as a nasal spray for anxiety-related conditions but has never been evaluated by the FDA, EMA, or other major Western regulatory agencies. The clinical evidence base is predominantly Russian-language.
68 published studies: 15 human, 49 animal, 3 in-vitro, 3 reviews
Selank is approved in Russia for anxiety-related conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies.
The key clinical study (62 patients) compared Selank to a benzodiazepine in generalised anxiety disorder and reported comparable effects. Published clinical studies are predominantly Russian and have not undergone Western regulatory review. The evidence base does not meet FDA or EMA approval standards. Its regulatory status is limited to Russia and certain former Soviet states.
Research suggests Selank may modulate GABAergic signalling pathways and influence gene expression related to neurotransmitter systems. These proposed mechanisms are based on animal studies and gene expression analyses. The evidence has not been evaluated through FDA or EMA regulatory review processes.
Research suggests the key clinical study (62 patients) compared Selank to a benzodiazepine for generalised anxiety disorder and reported comparable effects with notable advantages: no sedation, no tolerance, no dependence, and no withdrawal symptoms. However, this study is small by Western standards and may not have met modern double-blinding requirements. Only three published clinical studies are available on major databases, with the largest involving 70 patients. No head-to-head comparisons with first-line Western anxiolytics (SSRIs, buspirone) exist. A puzzling feature is the extremely short blood half-life (2 minutes) despite hours-long therapeutic effects — a disconnect that is mechanistically unexplained. Products from unregulated channels lack pharmaceutical quality assurance.
Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With Dyslexia
Effects of Transcranial Magnetic Stimulation on Object Recognition
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Pinealon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. The evidence base consists of in vitro cell studies and animal experiments published primarily by the originating research group. As with other Khavinson bioregulator peptides, the proposed mechanisms and the underlying theoretical framework have not been evaluated through conventional Western regulatory processes. Products available through unregulated channels lack pharmaceutical quality assurance.
Semax is approved in Russia for stroke recovery and cognitive conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies, and the clinical evidence base has not undergone Western regulatory review. Published clinical studies are predominantly Russian. The largest published study (110 stroke patients) reported correlations between treatment and BDNF levels. The evidence does not meet the standards typically required for FDA or EMA approval. Its regulatory status is limited to Russia and certain former Soviet states.
Dihexa has no marketing authorisation. No human clinical trials have been conducted. The foundational research by the originating laboratory faces serious integrity concerns: a key paper (McCoy et al., 2013) received an expression of concern for image manipulation, and a second paper (Benoist et al., 2014) was retracted after institutional investigation found falsified and fabricated data. These integrity issues fundamentally undermine the evidence base for dihexa. Products available through unregulated channels are based on research that has been formally questioned or retracted by the scientific community. This compound carries unique evidence quality concerns beyond the standard limitations of other research compounds.
